<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CIPROFLOXACIN HYDROCHLORIDE
                 - ciprofloxacin hydrochloride solution </strong><br>STAT Rx USA LLC<br></p></div>
<h1>
<span class="Bold">Ciprofloxacin Hydrochloride Ophthalmic Solution</span><br>0.3% as base<br>Sterile
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-1"></a><p></p>
<h1>
DESCRIPTION
</h1>
<p class="First">Ciprofloxacin Hydrochloride Ophthalmic Solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid. It is a <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> to light yellow crystalline powder with a molecular weight of 385.8. Its empirical formula is C<span class="Sub">17</span>H<span class="Sub">18</span>FN<span class="Sub">3</span>O<span class="Sub">3</span>•HCl•H<span class="Sub">2</span>O and its chemical structure is as follows:</p>
<br><p><img alt="CIPRO CHEM STRUCT Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=11f56251-d913-4986-9dba-c2e4df8a3822&amp;name=CIPRO%20CHEM%20STRUCT.jpg"></p>
<p><br></p>
<p></p>
<p>Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position.</p>
<p>Each mL of Ciprofloxacin Hydrochloride Ophthalmic Solution contains: <span class="Bold">Active: </span>ciprofloxacin HCl 3.5 mg equivalent to 3 mg base. <span class="Bold">Preservative: </span>benzalkonium chloride 0.006%. <span class="Bold">Inactive: </span>sodium acetate, acetic acid, mannitol 4.6%, edetate disodium 0.05%, hydrochloric acid and/or sodium hydroxide (to adjust pH) and purified water. The pH is approximately 4.5 and the <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> is approximately 300 mOsm.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-2"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY
</h1>
<p class="First"><span class="Bold">Systemic Absorption: </span>A systemic absorption study was performed in which Ciprofloxacin Hydrochloride Ophthalmic Solution was administered in each eye every two hours while awake for two days followed by every four hours while awake for an additional 5 days. The maximum reported plasma concentration of ciprofloxacin was less than 5 ng/mL. The mean concentration was usually less than 2.5 ng/mL.</p>
<p><span class="Bold">Microbiology: </span>Ciprofloxacin has <span class="Italics">in vitro </span>activity against a wide range of gram-negative and gram-positive organisms. The bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase which is needed for the synthesis of bacterial DNA.</p>
<p>Ciprofloxacin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. (See <span class="Underline"><a href="#splSectionIndicationsUsage">INDICATIONS AND USAGE</a></span> section).</p>
<p><span class="Bold">Gram-Positive:</span></p>
<p><span class="Italics">Staphylococcus aureus</span></p>
<p><span class="Italics">Staphylococcus epidermidis</span></p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Streptococcus (Viridans Group)</span></p>
<p><span class="Bold">Gram-Negative:</span></p>
<p><span class="Italics">Haemophilus influenzae</span></p>
<p><span class="Italics">Pseudomonas aeruginosa</span></p>
<p><span class="Italics">Serratia marcescens</span></p>
<p>Ciprofloxacin has been shown to be active <span class="Italics">in vitro </span>against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms, however, <span class="Italics">the clinical significance of these data is unknown:</span></p>
<p><span class="Bold">Gram-Positive:</span></p>
<p><span class="Italics">Enterococcus faecalis </span>(Many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are only moderately susceptible)</p>
<p><span class="Italics">Staphylococcus haemolyticus</span></p>
<p><span class="Italics">Staphylococcus hominis</span></p>
<p><span class="Italics">Staphylococcus saprophyticus</span></p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p><span class="Bold">Gram-Negative:</span></p>
<p><span class="Italics">Acinetobacter calcoaceticus subsp. anitratus</span></p>
<p><span class="Italics">Aeromonas caviae</span></p>
<p><span class="Italics">Aeromonas hydrophila</span></p>
<p><span class="Italics">Brucella melitensis</span></p>
<p><span class="Italics">Campylobacter coli</span></p>
<p><span class="Italics">Campylobacter jejuni</span></p>
<p><span class="Italics">Citrobacter diversus</span></p>
<p><span class="Italics">Citrobacter freundii</span></p>
<p><span class="Italics">Edwardsiella tarda</span></p>
<p><span class="Italics">Enterobacter aerogenes</span></p>
<p><span class="Italics">Enterobacter cloacae</span></p>
<p><span class="Italics">Escherichia coli</span></p>
<p><span class="Italics">Haemophilus ducreyi</span></p>
<p><span class="Italics">Haemophilus parainfluenzae</span></p>
<p><span class="Italics">Klebsiella pneumoniae</span></p>
<p><span class="Italics">Klebsiella oxytoca</span></p>
<p><span class="Italics">Legionella pneumophila</span></p>
<p><span class="Italics">Moraxella (Branhamella) catarrhalis</span></p>
<p><span class="Italics">Morganella morganii</span></p>
<p><span class="Italics">Neisseria gonorrhoeae</span></p>
<p><span class="Italics">Neisseria meningitidis</span></p>
<p><span class="Italics">Pasteurella multocida</span></p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p><span class="Italics">Proteus vulgaris</span></p>
<p><span class="Italics">Providencia rettgeri</span></p>
<p><span class="Italics">Providencia stuartii</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> enteritidis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhi</span></p>
<p><span class="Italics">Shigella sonneii</span></p>
<p><span class="Italics">Shigella flexneri</span></p>
<p><span class="Italics">Vibrio cholerae</span></p>
<p><span class="Italics">Vibrio parahaemolyticus</span></p>
<p><span class="Italics">Vibrio vulnificus</span></p>
<p><span class="Italics">Yersinia enterocolitica</span></p>
<p><span class="Bold">Other Organisms: </span><span class="Italics">Chlamydia trachomatis </span>(only moderately susceptible) and <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> </span>(only moderately susceptible).</p>
<p>Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pseudomonas cepacia </span>and some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pseudomonas maltophilia </span>are resistant to ciprofloxacin as are most anaerobic bacteria, including <span class="Italics">Bacteroides fragilis </span>and <span class="Italics">Clostridium difficile</span>.</p>
<p>The minimal bactericidal concentration (MBC) generally does not exceed the minimal inhibitory concentration (MIC) by more than a factor of 2. Resistance to ciprofloxacin <span class="Italics">in vitro </span>usually develops slowly (multiple-step mutation).</p>
<p>Ciprofloxacin does not cross-react with other antimicrobial agents such as beta-lactams or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin.</p>
<p><span class="Bold">Clinical Studies:</span></p>
<p>Following therapy with Ciprofloxacin Hydrochloride Ophthalmic Solution, 76% of the patients with <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcers</span> and positive bacterial cultures were clinically cured and complete re-epithelialization occurred in about 92% of the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>.</p>
<p>In 3 and 7 day multicenter clinical trials, 52% of the patients with <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and positive conjunctival cultures were clinically cured and 70-80% had all causative pathogens eradicated by the end of treatment.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-3"></a><p></p>
<h1>
INDICATIONS AND USAGE
</h1>
<p class="First">Ciprofloxacin Hydrochloride Ophthalmic Solution is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed below:</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">Corneal Ulcers</span>: </span></p>
<p><span class="Italics">Pseudomonas aeruginosa</span></p>
<p><span class="Italics">Serratia marcescens*</span></p>
<p><span class="Italics">Staphylococcus aureus</span></p>
<p><span class="Italics">Staphylococcus epidermidis</span></p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Streptococcus </span>(Viridans Group)*</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>: </span></p>
<p><span class="Italics">Haemophilus influenzae</span></p>
<p><span class="Italics">Staphylococcus aureus</span></p>
<p><span class="Italics">Staphylococcus epidermidis</span></p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p>*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-4"></a><p></p>
<h1>
CONTRAINDICATIONS
</h1>
<p class="First">A history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ciprofloxacin or any other component of the medication is a contraindication to its use. A history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other quinolones may also contraindicate the use of ciprofloxacin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="splSectionWarnings"></a><a name="section-5"></a><p></p>
<h1>
WARNINGS
</h1>
<p class="First">NOT FOR INJECTION INTO THE EYE.</p>
<p>Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolone therapy. Some reactions were accompanied by <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, pharyngeal or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>. Only a few patients had a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated.</p>
<p>Remove contact lenses before using.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="splSectionPrecautions"></a><a name="section-6"></a><p></p>
<h1>
PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-6.1"></a><p></p>
<h2>
General
</h2>
<p class="First">As with other antibacterial preparations, prolonged use of ciprofloxacin may result in overgrowth of nonsusceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, appropriate therapy should be initiated. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. </p>
<p>Ciprofloxacin should be discontinued at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.</p>
<p>In clinical studies of patients with <span class="product-label-link" type="condition" conceptid="4335899" conceptname="Bacterial corneal ulcer">bacterial corneal ulcer</span>, a white crystalline precipitate located in the superficial portion of the corneal defect was observed in 35 (16.6%) of 210 patients. The onset of the precipitate was within 24 hours to 7 days after starting therapy. In one patient, the precipitate was immediately irrigated out upon its appearance. In 17 patients, resolution of the precipitate was seen in 1 to 8 days (seven within the first 24-72 hours), in five patients, resolution was noted in 10-13 days. In nine patients, exact resolution days were unavailable; however, at follow-up examinations, 18-44 days after onset of the event, complete resolution of the precipitate was noted. In three patients, outcome information was unavailable. The precipitate did not preclude continued use of ciprofloxacin, nor did it adversely affect the clinical course of the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or visual outcome. (SEE ADVERSE REACTIONS).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-6.2"></a><p></p>
<h2>
Information for patients
</h2>
<p class="First">Do not touch dropper tip to any surface, as this may contaminate the solution.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPrecautionsDrugInteract"></a><a name="section-6.3"></a><p></p>
<h2>
Drug Interactions
</h2>
<p class="First">Specific drug interaction studies have not been conducted with ophthalmic ciprofloxacin. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, enhance the effects of the oral anticoagulant, warfarin, and its derivatives and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPrecautionsCarcinogen"></a><a name="section-6.4"></a><p></p>
<h2>
Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Eight <span class="Italics">in vitro </span>mutagenicity tests have been conducted with ciprofloxacin and the test results are listed below:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>/Microsome Test (Negative)</p>
<p><span class="Italics">E. coli </span>DNA Repair Assay (Negative)</p>
<p>Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell Forward Mutation Assay (Positive)</p>
<p>Chinese Hamster V79 Cell HGPRT Test (Negative)</p>
<p>Syrian Hamster Embryo Cell Transformation Assay (Negative)</p>
<p><span class="Italics">Saccharomyces cerevisiae </span>Point Mutation Assay (Negative)</p>
<p><span class="Italics">Saccharomyces cerevisiae </span>Mitotic Crossover and Gene Conversion Assay (Negative)</p>
<p>Rat Hepatocyte DNA Repair Assay (Positive)</p>
<p>Thus, two of the eight tests were positive, but the results of the following three <span class="Italics">in vivo </span>test systems gave negative results:</p>
<p>Rat Hepatocyte DNA Repair Assay</p>
<p>Micronucleus Test (Mice)</p>
<p>Dominant Lethal Test (Mice)</p>
<p>Long-term carcinogenicity studies in mice and rats have been completed. After daily oral dosing for up to two years, there is no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-6.5"></a><p></p>
<h2>
Pregnancy
</h2>
<p class="First"><span class="Bold">Pregnancy Category C: </span>Reproduction studies have been performed in rats and mice at doses up to six times the usual daily human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to ciprofloxacin. In rabbits, as with most antimicrobial agents, ciprofloxacin (30 and 100 mg/kg orally) produced <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> resulting in maternal <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> and an increased incidence of abortion. No <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed at either dose. After intravenous administration, at doses up to 20 mg/kg, no maternal toxicity was produced and no embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed. There are no adequate and well-controlled studies in pregnant women. Ciprofloxacin Hydrochloride Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-7"></a><p></p>
<h1>
Nursing Mothers
</h1>
<p class="First">It is not known whether topically applied ciprofloxacin is excreted in human milk; however, it is known that orally administered ciprofloxacin is excreted in the milk of lactating rats and oral ciprofloxacin has been reported in human breast milk after a single 500 mg dose. Caution should be exercised when Ciprofloxacin Hydrochloride Ophthalmic Solution is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-8"></a><p></p>
<h1>
Pediatric Use
</h1>
<p class="First">Safety and effectiveness in pediatric patients below the age of 1 year have not been established.</p>
<p>Although ciprofloxacin and other quinolones cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals after oral administration, topical ocular administration of ciprofloxacin to immature animals did not cause any <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> and there is no evidence that the ophthalmic dosage form has any effect on the weight bearing joints.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPrecautionsGeriatric"></a><a name="section-9"></a><p></p>
<h1>
Geriatric Use
</h1>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-10"></a><p></p>
<h1>
ADVERSE REACTIONS
</h1>
<p class="First">The most frequently reported drug related adverse reaction was local burning or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>. In <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcer</span> studies with frequent administration of the drug, white crystalline precipitates were seen in approximately 17% of patients (SEE PRECAUTIONS). Other reactions occurring in less than 10% of patients included lid margin crusting, crystals/scales, foreign body sensation, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span> and a bad taste following instillation. Additional events occurring in less than 1% of patients included <span class="product-label-link" type="condition" conceptid="4080997" conceptname="Corneal epithelial staining pattern">corneal staining</span>, <span class="product-label-link" type="condition" conceptid="436695" conceptname="Band-shaped keratopathy">keratopathy</span>/<span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, lid <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, tearing, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4232690" conceptname="Infiltrate of cornea">corneal infiltrates</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and decreased vision.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionOverdose"></a><a name="section-11"></a><p></p>
<h1>
OVERDOSAGE
</h1>
<p class="First">A topical <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of Ciprofloxacin Hydrochloride Ophthalmic Solution may be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> from the eye(s) with warm tap water.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-12"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION
</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">Corneal Ulcers</span>: </span>The recommended dosage regimen for the treatment of <span class="Bold"><span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcers</span> </span>is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred.</p>
<p><span class="Bold">Bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>: </span>The recommended dosage regimen for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> is one or two drops instilled into the conjunctival sac(s) every two hours while awake for two days and one or two drops every four hours while awake for the next five days.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-13"></a><p></p>
<h1>
HOW SUPPLIED
</h1>
<p class="First">As a sterile ophthalmic solution in Alcon's DROP-TAINER** dispensing system consisting of a natural low density polyethylene bottle and dispensing plug and tan polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package.</p>
<p><br></p>
<p><span class="Bold">5 mL </span> -  <span class="Bold">NDC </span># 16590-421-05</p>
<p><br></p>
<p><span class="Bold">STORAGE: </span>Store at 2° to 25°C (36° to 77°F). Protect from light.</p>
<br><p><span class="Bold">Relabeling and Repackaging by</span>:<br>STAT Rx USA LLC<br>Gainesville, GA  30501<br></p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="splSectionAnimalPharm"></a><a name="section-14"></a><p></p>
<h1>
ANIMAL PHARMACOLOGY
</h1>
<p class="First">Ciprofloxacin and related drugs have been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of most species tested following oral administration.</p>
<p>However, a one-month topical ocular study using immature Beagle dogs did not demonstrate any articular lesions.</p>
<p><span class="Bold">Rx Only</span></p>
<p>Revised: July 2007</p>
<p>**DROP-TAINER is a registered trademark of Alcon Manufacturing, Ltd.</p>
<p><span class="Bold">9002761-0707</span></p>
<p>Dist. By:</p>
<p><span class="Bold">FALCON Pharmaceuticals, Ltd.</span></p>
<p>For t Worth, Texas 76134 USA</p>
<p>Mfd. By:</p>
<p><span class="Bold">ALCON LABORATORIES, INC.</span></p>
<p>For t Worth, Texas 76134 USA</p>
<p>Printed in USA</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="L509a670c-2347-4fce-9314-b4f09c9dd919"></a><a name="section-15"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Relabeling and Repackaging by:</span></p>
<p>STAT Rx USA LLC</p>
<p>Gainesville, GA  30501</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-16"></a><p></p>
<h1>PACKAGE LABEL - CIPROFLOXACIN OPTH SOLN 0.3% - 5mL

</h1>
<br><p class="First"><img alt="CIPRO OPTH SOLN 3_5 mg LABEL Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=11f56251-d913-4986-9dba-c2e4df8a3822&amp;name=CIPRO%20OPTH%20SOLN%203_5%20mg%20LABEL.jpg"></p>
<p><span class="Bold"><span class="Bold"><br></span></span></p>
<p><span class="Bold"><span class="Bold">Rx Only</span></span></p>
<p><span class="Bold">FALCON PHARMACEUTICALS®</span></p>
<p><span class="Bold">Ciprofloxacin Hydrochloride Ophthalmic Solution, 0.3%</span></p>
<p><span class="Bold">as base 0.3% 10 mL</span> STERILE</p>
<p>AFFILIATE OF</p>
<p>ALCON LABORATORIES, INC.</p>
<p><br></p>
<p></p>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CIPROFLOXACIN HYDROCHLORIDE
                 		
					</strong><br><span class="contentTableReg">ciprofloxacin hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-421(NDC:61314-656)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CIPROFLOXACIN HYDROCHLORIDE</strong> (CIPROFLOXACIN) </td>
<td class="formItem">CIPROFLOXACIN HYDROCHLORIDE</td>
<td class="formItem">3.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-421-05</td>
<td class="formItem">5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA019992</td>
<td class="formItem">05/07/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT Rx USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PSS World Medical Inc. (101822682)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT Rx USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">relabel(16590-421), repack(16590-421)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ffaef770-f31e-4ed0-b35c-aedf2b7a57c2</div>
<div>Set id: 11f56251-d913-4986-9dba-c2e4df8a3822</div>
<div>Version: 1</div>
<div>Effective Time: 20121011</div>
</div>
</div> <div class="DistributorName">STAT Rx USA LLC</div></p>
</body></html>
